Evidence map›Paper›PMID 42077470›Full record

ArticleInternational journal of genomics2026

CEACAM1 Is Associated With an Immune-Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma.

Ziqi Cao, Minjue Shan, Yadong Guo, Mengmei Zhang, Ziyou Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ziqi CaoDepartment of Surgery, Heilongjiang University of Chinese Medicine Affiliated Second Hospital, Harbin, 150001, China.
Minjue ShanSchool of Medicine, Tongji University, Shanghai, 200092, China, tongji.edu.cn.ORCID https://orcid.org/0009-0009-0702-886X
Yadong GuoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0000-0002-6684-7015
Mengmei ZhangDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0009-0003-5412-0083
Ziyou LinSchool of Medicine, Tongji University, Shanghai, 200092, China, tongji.edu.cn.ORCID https://orcid.org/0009-0009-7607-0682

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a multifunctional immunomodulatory protein involved in both immune activation and immune suppression across diverse cancer types. However, its biological significance and clinical relevance in sarcoma (SARC) remain poorly defined. A comprehensive multiomics analysis of CEACAM1 was performed by integrating transcriptomic, genomic, epigenetic, immunological, and pharmacogenomic data from TCGA, GTEx, CPTAC, and large-scale drug sensitivity datasets. CEACAM1 expression patterns, prognostic value, immune infiltration characteristics, pathway associations, genomic alterations, DNA methylation, transcriptional regulation, and therapeutic response were systematically evaluated. In SARC, elevated CEACAM1 expression was significantly associated with favorable clinical outcomes and characterized by an immune-enriched tumor microenvironment. High CEACAM1 expression correlated with increased CD8

Indexed as

CEACAM1immunotherapy responsesarcomatumor immune microenvironment

Identifiers

PMID42077470
PMCPMC13130855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.